Enrico Franceschi1, Marco Bartolotti1, Alicia Tosoni1, Stefania Bartolini1, Carmelo Sturiale2, Antonio Fioravanti2, Eugenio Pozzati2, Renato Galzio3, Andrea Talacchi4, Lorenzo Volpin5, Luca Morandi6, Daniela Danieli7, Mario Ermani8, Alba A Brandes9. 1. Department of Medical Oncology, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy. 2. Department of Neurosurgery, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy. 3. Department of Health Sciences, University of L'Aquila, L'Aquila, Italy. 4. Section of Neurosurgery, Department of Neurological, Neuropsychological, Morphological and Movement Sciences, University of Verona, University Hospital, Verona, Italy. 5. Department of Neuroscience and Neurosurgery, San Bortolo Hospital, Vicenza, Italy. 6. Department of Biomedical and NeuroMotor Sciences (DiBiNeM), University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital, Bologna, Italy. 7. Pathology Department, San Bortolo Hospital, Vicenza, Italy. 8. Department of Neurosciences, Statistic and Informatic Unit, Azienda Ospedale-Università, Padova, Italy. 9. Department of Medical Oncology, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy alba.brandes@yahoo.it.
Abstract
BACKGROUND: Treatment options for glioblastoma (GBM) at recurrence have limited efficacy. Re-surgery has been used for confirmation of recurrent disease and to provide relief of symptoms but the real impact on survival is unknown. PATIENTS AND METHODS: A retrospective analysis was performed for GBM patients followed between 01/2005 and 06/2010 at our Institution. RESULTS: Two hundred and thirty-two patients with recurrent GBM were evaluated. One hundred and two patients (44%) were treated with re-surgery followed by chemotherapy and 130 patients (56%) with chemotherapy alone. In multivariate analysis, no significant effect of re-surgery was found, with age (p=0.001), MGMT methylation (p=0.002) and PFS at 6 months (p=0.0001) being significant prognostic factors. CONCLUSION: Second surgery might have a limited impact in the clinical course of recurrent GBM patients. Copyright
BACKGROUND: Treatment options for glioblastoma (GBM) at recurrence have limited efficacy. Re-surgery has been used for confirmation of recurrent disease and to provide relief of symptoms but the real impact on survival is unknown. PATIENTS AND METHODS: A retrospective analysis was performed for GBM patients followed between 01/2005 and 06/2010 at our Institution. RESULTS: Two hundred and thirty-two patients with recurrent GBM were evaluated. One hundred and two patients (44%) were treated with re-surgery followed by chemotherapy and 130 patients (56%) with chemotherapy alone. In multivariate analysis, no significant effect of re-surgery was found, with age (p=0.001), MGMT methylation (p=0.002) and PFS at 6 months (p=0.0001) being significant prognostic factors. CONCLUSION: Second surgery might have a limited impact in the clinical course of recurrent GBM patients. Copyright
Authors: T Hundsberger; A F Hottinger; U Roelcke; P Roth; D Migliorini; P Y Dietrich; K Conen; G Pesce; E Hermann; A Pica; M W Gross; D Brügge; L Plasswilm; M Weller; P M Putora Journal: J Neurooncol Date: 2015-10-12 Impact factor: 4.130
Authors: T Huber; G Alber; S Bette; T Boeckh-Behrens; J Gempt; F Ringel; E Alberts; C Zimmer; J S Bauer Journal: Clin Neuroradiol Date: 2015-10-21 Impact factor: 3.649